2-氨基-4,6-二氯-5-乙基嘧啶 | 6343-68-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-4,6-二氯-5-乙基嘧啶
• 英文名称: 4,6-dichloro-5-ethylpyrimidin-2-amine
• CAS: 6343-68-6
• 化学式: C₆H₇Cl₂N₃
• mdl: MFCD11110662
• 分子量: 192.048
• InChiKey: RFDSRYRJLQXWBR-UHFFFAOYSA-N

物化性质

• 沸点：
  349.9±52.0 °C(Predicted)
• 密度：
  1.423±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  2-氨基-4,6-二氯-5-乙基嘧啶 在 磷化氢 、 氨 、 氢碘酸 作用下， 生成 5-乙基嘧啶-2,4-二胺
  参考文献：
  名称：

  v. Merkatz, Chemische Berichte, 1919, vol. 52, p. 876

  摘要：

  DOI：
• 作为产物：
  描述：

  乙基丙二酸二乙酯 在 盐酸 、 水 、 sodium 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 6.0h， 生成 2-氨基-4,6-二氯-5-乙基嘧啶
  参考文献：
  名称：

  5-Substituted 2-amino-4,6-dihydroxypyrimidines and 2-amino-4,6-dichloropyrimidines: synthesis and inhibitory effects on immune-activated nitric oxide production

  摘要：

  A series of 5-substituted 2-amino-4,6-dihydroxypyrimidines were prepared by a modified condensation of the corresponding monosubstituted malonic acid diesters with guanidine in an excess of sodium ethoxide. The optimized procedure using Vilsmeier-Haack-Arnold reagent, followed by immediate deprotection of the (dimethylamino)methylene protecting groups, has been developed to convert the 2-amino-4,6-dihydroxypyrimidine analogs to novel 5-substituted 2-amino-4,6-dichloropyrimidines in high yields. Pilot screening for biological properties of the prepared compounds was done in mouse peritoneal cells using the in vitro nitric oxide (NO) assay. Irrespective of the substituent at the 5 position, 2-amino-4,6-dichloropyrimidines inhibited immune-activated NO production. The most effective was 5-fluoro-2-amino-4,6-dichloropyrimidine with an IC ₅₀ of 2 µM (higher activity than the most potent reference compound) while the IC ₅₀s of other derivatives were within the range of 9-36 µM. The 2-amino-4,6-dihydroxypyrimidine counterparts were devoid of any NO-inhibitory activity. The compounds had no suppressive effects on the viability of cells. The Mechanism of action remains to be elucidated.

  DOI：

  10.1007/s00044-014-1018-9

文献信息

• [EN] PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINE INHIBANT LA FORMATION D'OXYDE NITRIQUE ET PROSTAGLANDINE E2, LEUR PROCÉDÉ DE PRODUCTION ET LEUR UTILISATION
  申请人：USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR V V I

  公开号：WO2012116666A1

  公开（公告）日：2012-09-07

  The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.˙

  该发明提供了一般式(I)的嘧啶化合物，可以同时减少一氧化氮（NO）和前列腺素E2（PGE2）的产生。它们在降低这些因子产生达到50%的浓度下对细胞的存活性没有负面影响；它们不具有细胞毒性。此外，还提供了一种制备一般式(I)的带有2-甲酰胺基团的嘧啶化合物的方法，一种包括根据该发明的取代嘧啶化合物的药物组合物，以及利用这些化合物治疗炎症和癌症疾病的方法。
• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE
  申请人：VERTEX PHARMA

  公开号：WO2022076627A1

  公开（公告）日：2022-04-14

  This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies and combination pharmaceuticals employing those modulators, and processes and intermediates for making such modulators.

  本公开提供囊性纤维化跨膜传导调节因子（CFTR）的调节剂，其具有以下核心结构：，包含至少一种这样的调节剂的药物组合物，使用这样的调节剂和药物组合物治疗CFTR介导的疾病，包括囊性纤维化的方法，使用这些调节剂的组合疗法和组合药物，以及制造这些调节剂的过程和中间体。
• PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF
  申请人：Ustav Organicke Chemie a Biochemie Akademie Ved CR, v.v.i.

  公开号：US20130324566A1

  公开（公告）日：2013-12-05

  The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.

  本发明提供了一种通式（I）的嘧啶化合物，它们能同时减少一氧化氮（NO）和前列腺素E2（PGE2）的产生。它们在浓度减少这些因子的产生高达50％时，对细胞的生存能力没有负面影响，也不具有细胞毒性。此外，本发明还提供了一种制备带有2-甲酰胺基团的嘧啶化合物的方法，以及包含根据本发明所述的取代嘧啶化合物的制药组合物，以及使用这些化合物治疗炎症和癌症疾病的方法。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：EXELIXIS, INC.

  公开号：US20140107100A1

  公开（公告）日：2014-04-17

  The invention is directed 10 Compound's of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及公式I的化合物，以及其药学上可接受的盐或溶剂化物，以及制备和使用这些化合物的方法。
• [EN] NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRIMIDIN-2-YL SULFONAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2022180136A1

  公开（公告）日：2022-09-01

  The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, X1and X2are as described herein, composition including the compounds and methods of using the compounds.

  本发明涉及具有一般式（I）的新化合物，其中R1、R2、R3、R4、X1和X2如本文所述，包括该化合物的组合物以及使用该化合物的方法。